Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Position in Hologic, Inc. $HOLX

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 36.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 284,181 shares of the medical equipment provider’s stock after selling 164,709 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Hologic worth $18,517,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic in the second quarter worth $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in Hologic in the 1st quarter worth $34,000. Cromwell Holdings LLC boosted its holdings in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Hologic in the 1st quarter worth $42,000. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $74.11 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $80.31. The business has a 50 day simple moving average of $70.06 and a two-hundred day simple moving average of $66.04. The stock has a market capitalization of $16.48 billion, a PE ratio of 30.75, a P/E/G ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.During the same period in the prior year, the firm earned $1.01 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Leerink Partners boosted their price objective on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Finally, Morgan Stanley boosted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.